Xaira Therapeutics
AI-native drug discovery with $1B+ launch — largest in biotech history
Xaira Therapeutics launched in April 2024 with over $1 billion in committed funding — the largest venture-backed launch in biotech history. Co-founded by Nobel laureate David Baker and led by former Genentech CSO Marc Tessier-Lavigne, Xaira combines cutting-edge protein and antibody design AI (RFdiffusion, RFantibody) with deep drug development expertise. The company's board includes former FDA Commissioner Scott Gottlieb, Nobel laureate Carolyn Bertozzi, and former J&J CEO Alex Gorsky.
Antibody Design, Generative Chemistry, Structure Prediction, Foundation Models
RFdiffusion, RFantibody
Funding
$1B+
Total raised
$1B+
Led by Arch Venture Partners, Foresite Labs
Arch Venture Partners · Foresite Labs · F-Prime · NEA · Sequoia Capital · Lux Capital · Lightspeed Venture Partners
Technology
AI-native drug discovery platform built on frontier protein and antibody design models from David Baker's lab. RFdiffusion generates novel protein structures, and RFantibody designs antibodies de novo. The platform combines these generative AI capabilities with large-scale data generation and therapeutic product development.
Leadership
Marc Tessier-Lavigne
CEO
Former CSO at Genentech, former President of Stanford University
David Baker
Co-Founder
Nobel Prize in Chemistry 2024, Director of Institute for Protein Design at UW
Similar companies
Boltz PBC
Open-source biomolecular AI for drug discovery
platform · 2026Chai Discovery
Foundation models for molecular discovery with zero-shot antibody design
platform · 2024EvolutionaryScale
ESM3 — the largest protein language model, generating novel proteins
platform · 2023Generate:Biomedicines
Generative AI for de novo protein therapeutic design
preclinical · 2020Get updates on Xaira Therapeutics
We'll notify you when we publish updates about Xaira Therapeutics.